Filing Flows › Nurix Therapeutics (NRIX) › Q3 FY26 › vs Q2 FY26
Nurix Therapeutics (NRIX) Q3 FY26 vs Q2 FY26 (quarter over quarter)
Nurix Therapeutics's revenue rose $664M (74×) from $9.0M in Q2 FY26 to $673M in Q3 FY26. Net margin 81.7% against -990.1% (+1071.8 pts).
Nurix Therapeutics, Q3 FY26: revenue $673M (85× year over year), operating margin 83.1%, net earnings $550M, operating cash flow $616M. The chart draws each line against Q2 FY26, the increases inside each band.
Margins
| Q3 FY26 | Q2 FY26 | Change | |
|---|---|---|---|
| Net margin | 81.7% | -990.1% | +1071.8 pts |
Every line
| Line | Q3 FY26 | Q2 FY26 | Change | % |
|---|---|---|---|---|
| Revenue | $673M | $9.0M | $664M | 74× |
| Other income, net | $4.0M | $4.4M | −$436K | -10% |
| Operating profit | $559M | −$94.2M | $654M | — |
| Costs & expenses | $114M | $103M | $10.4M | +10% |
| Pre-tax earnings | $563M | −$89.8M | $653M | — |
| Research & development | $79.3M | $87.7M | −$8.4M | -10% |
| General & admin | $34.4M | $15.6M | $18.8M | +120% |
| Net earnings | $550M | −$89.5M | $639M | — |
| Income tax | $13.6M | −$271K | $13.9M | — |
| Depreciation & amortization | $2.1M | $2.3M | −$116K | -5% |
| Share-based compensation | $10.8M | $11.4M | −$611K | -5% |
| Working capital & other | $52.9M | −$20.7M | $73.6M | — |
| Operating cash flow | $616M | −$96.6M | $712M | — |
| Free cash flow (OCF − capex) | $614M | −$98.5M | $713M | — |
| Capital expenditures | $1.4M | $1.9M | −$544K | -28% |
Questions
How much did Nurix Therapeutics's revenue grow quarter over quarter in Q3 FY26?
Nurix Therapeutics's revenue rose $664M (74×) from $9.0M in Q2 FY26 to $673M in Q3 FY26. Net margin 81.7% against -990.1% (+1071.8 pts).